A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for o

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Muscle-invasive Urothelial Carcinoma Of The Bladder
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically proven, cT2-T4a N0, M0 infiltrating urothelial carcinoma of the bladder
    2. Patients with no residual tumor, or intravesical tumor size of =3 cm following TURBT are eligible
    3. Patients must refuse cisplatin-based com

You may not be eligible for this study if the following are true:

    1. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study
    2. Received prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy wi

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.